Role of Endoscopic Management in Ulcerative Colitis Patients with Dysplasia

Cleveland, Noa Krugliak; DiNardi, Nicholas; Rubin, David T.

doi:10.1007/978-3-030-16755-4_28

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Overall, management of dysplasia in IBD patients requires complex decision-making that should incorporate patient values and goals of care with consideration of patient-related risk factors (family history of cancer), disease-related risk factors (duration, primary sclerosing cholangitis, prior dysplasia), dysplasia-related risk factors (grade, location), and availability of endoscopic and surgical expertise. 27…”

Section: Resection Considerationsmentioning

confidence: 99%

Management of Dysplasia in Inflammatory Bowel Disease

Rubens

Smith

2023

Clin Colon Rectal Surg

View full text Add to dashboard Cite

Given the chronic nature of mucosal inflammation present in patients with inflammatory bowel disease (IBD), there is a high risk of dysplastic lesions progressing to cancer, in addition to a high risk of synchronous and/or metachronous cancers developing in those diagnosed with dysplasia. Due to this, consensus guidelines recommend regular surveillance. When visible dysplasia is encountered, options include endoscopic or surgical resection depending on characteristics of the lesion. Advancements in endoscopic tools increasingly allow for endoscopic removal when appropriate. Invisible dysplasia discovered on random biopsy should prompt referral to physicians who specialize in IBD. While surgical resection with proctocolectomy significantly decreases the risk of colorectal cancer, the risk must be balanced against the morbidity of surgery and quality-of-life concerns. Management of dysplasia in IBD patients requires complex decision-making that requires balance of patient values and goals of care with cancer-related risk factors.

show abstract

Section: Resection Considerationsmentioning

confidence: 99%